SCHEMBL6136157

SCHEMBL6136157

COc1ccc(N(C)C(=O)NCCc2cccc(Cc3c(-c4ccc(O)cc4)ccc4cc(O)ccc34)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.40
▸ ESR2 Q92731 2/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ OPRM1 P35372 2/20 0.39
▸ OPRD1 P41143 2/20 0.39
▸ OPRK1 P41145 2/20 0.39
▸ MTNR1A P48039 7/20 0.38
▸ MTNR1B P49286 6/20 0.38
▸ AKR1B10 O60218 1/20 0.36
▸ AKR1B1 P15121 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SPR P35270 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135927 0.94 ESR1 (0.38) ESR1ESR2ROCK2OPRM1OPRD1
SCHEMBL6136267 0.91 OPRM1 (0.40) ESR1ESR2OPRM1OPRD1OPRK1
SCHEMBL6136150 0.90 CNR1 (0.39) ESR1ESR2MTNR1AMTNR1BHSP90AA1
SCHEMBL6136242 0.86 ESR1 (0.47) ESR1ESR2ROCK2HSP90AA1PDK1
SCHEMBL6136033 0.85 CNR1 (0.49) ESR1ESR2ROCK2OPRM1OPRD1
SCHEMBL6136417 0.82 NPY5R (0.45) ESR1ESR2ROCK2MTNR1AMTNR1B
SCHEMBL6136101 0.80 ESR1 (0.46) ESR1ESR2ROCK2PDK1
SCHEMBL6136274 0.79 ROCK2 (0.41) ESR1ESR2ROCK2MTNR1AMTNR1B
SCHEMBL6136296 0.77 ESR1 (0.45) ESR1ESR2ROCK2PDK1PDK2
SCHEMBL6136126 0.77 TRPV1 (0.47) ESR1ESR2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback